Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
EyePoint, Inc. develops and commercializes therapeutics for serious retinal diseases as a clinical-stage biopharmaceutical company. Its lead product candidate, DURAVYU (vorolanib intravitreal insert), is an investigational sustained-delivery treatment that uses bioerodible Durasert E technology and is being studied for wet age-related macular degeneration and diabetic macular edema.
Recurring EyePoint news covers clinical program updates, financial results, FDA naming and product-status disclosures, manufacturing and commercial-readiness topics, investor presentations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Company updates also address cash resources, corporate development activity, and disclosures tied to its Nasdaq-listed common stock.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will have CEO Nancy Lurker speak at the Jefferies Healthcare Conference on June 2, 2021, at 9:30 a.m. ET. The session will explore the company's commitment to developing therapies for serious eye disorders, including innovations like EYP-1901, a treatment for wet age-related macular degeneration. Attendees can access a live webcast and a 90-day archive via EyePoint's website. The company also markets YUTIQ and DEXYCU for eye disorder treatments.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced successful enrollment completion for its Phase 1 trial of EYP-1901, a potential twice-yearly treatment for wet age-related macular degeneration (wet AMD). The trial includes dose escalation for patients previously responsive to anti-VEGF therapies. Interim data is expected in Q4 2021. EYP-1901 employs EyePoint’s Durasert technology for sustained delivery, potentially improving treatment outcomes for patients. The company aims to explore additional applications for EYP-1901, including diabetic retinopathy.
EyePoint Pharmaceuticals (EYPT) reported a productive first quarter of 2021, achieving net product revenues of $6.8 million, a 45% increase from $4.7 million in Q1 2020. The company completed a $115.1 million follow-on financing, enhancing its development pipeline. The Phase 1 DAVIO study for EYP-1901 targeting wet AMD is on track for initial data in Q4 2021. However, total net revenue declined slightly to $7.3 million from $7.5 million year-over-year. The net loss was $12.3 million, or ($0.50) per share, an improvement from a loss of $13.2 million in the same quarter last year.
EyePoint Pharmaceuticals (NASDAQ: EYPT) is set to host a conference call on May 5, 2021, at 8:30 a.m. ET to announce its Q1 2021 financial results and discuss corporate developments. The call will be accessible via phone and a live webcast on the company’s website. EyePoint focuses on therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained drug delivery. Its commercial products include YUTIQ® for chronic uveitis and DEXYCU® for postoperative inflammation.
EyePoint Pharmaceuticals (EYPT) reported financial results for Q4 and the full year ended December 31, 2020. Total net revenue increased to $34.4 million, up from $20.4 million in 2019. Net product revenue for the year was $20.8 million, compared to $16.8 million in the prior year. However, the company incurred a net loss of $45.4 million, or $3.54 per share. EyePoint raised $115.1 million through a public stock offering in February 2021, strengthening their financial position. They also highlighted progress in their EYP-1901 clinical trial for wet AMD.
EyePoint Pharmaceuticals (NASDAQ: EYPT) is set to present at two upcoming virtual conferences in March 2021. The first event is the Cowen Healthcare Conference on March 3, from 2:40-3:10 PM Eastern Time, featuring a fireside chat. The second event is the H.C. Wainwright Global Life Sciences Conference on March 9, at 7:00 AM Eastern Time, with a formal presentation. Investors can access a live webcast and archived replay on the company’s website for 90 days post-event. EyePoint focuses on therapeutics for serious eye disorders, leveraging Durasert® technology and offering products like YUTIQ® and DEXYCU®.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) will hold a conference call on March 4, 2021, at 8:30 a.m. ET to discuss its full year 2020 financial results and recent business highlights. The call can be accessed by dialing (877)-312-7507 or (631)-813-4828 with conference ID 1261618. The company focuses on developing therapeutics for serious eye disorders, leveraging Durasert® technology for sustained drug delivery. EyePoint has two commercial products: YUTIQ® and DEXYCU®.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has completed a public offering of 10,465,000 shares at $11.00 per share, raising approximately $115.1 million, post-underwriting expenses. The offering included an option for underwriters to purchase an additional 1,365,000 shares. The net proceeds will support the advancement of EYP-1901 for treating wet AMD, pipeline, commercial programs, and general corporate purposes. This was conducted under a previously filed shelf registration statement with the SEC.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced its intention to conduct an underwritten public offering of common stock. The offering is dependent on market conditions, with no certainty regarding its completion or specific terms. EyePoint plans to utilize the net proceeds for advancing EYP-1901, pipeline initiatives, and general corporate purposes. Underwriters Cowen and Guggenheim Securities will lead the offering, which is registered under Form S-3 with the SEC. A preliminary prospectus will provide additional details as it becomes available.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has initiated a Phase 1 clinical trial for EYP-1901, an innovative twice-yearly sustained delivery treatment targeting wet age-related macular degeneration (wet AMD). The trial will involve thirteen patients previously responsive to anti-VEGF treatments, focusing on safety and visual acuity outcomes. EYP-1901 utilizes the proprietary Durasert® technology combined with vorolanib, which previously showed efficacy in Phase 2 trials. This advancement could enhance treatment convenience and market potential, particularly for millions affected by wet AMD.